Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Monoclonal Antibody Research in the Era of COVID-19
share announcement

Monoclonal Antibody Research in the Era of COVID-19

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".

Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 2266

Special Issue Editor

Dr. Miaomiao Shi

E-Mail Website
Guest Editor
Missiakas-Schneewind Lab, University of Chicago, Building 204 9700 S. Cass Avenue, Lemont, IL 60439, USA
Interests: pathogenesis; vaccine and antibody development against Staphylococcus aureus

Special Issue Information

Dear Colleagues,

A monoclonal antibody is an antibody originating from a unique B cell lineage, binding only to the same epitope with high affinity for its target. Over the years, monoclonal antibodies have been used or heavily investigated for their potential role against many diseases, including bacterial and viral infection and cancer. Likewise, antibody-based therapy alone or in combination with other treatments has been demonstrated to be effective for both the early and late stages of SARS-COV-2 infection in the past three years.

In this Special Issue, we invite reviews, research papers, and clinical trial applications elaborating on mechanisms whereby monoclonal antibodies act directly and indirectly against various SARS-COV-2 variants and developing strategies and technologies for antibody engineering related to COVID-19 to enhance immune protection. additionally, new combinations of multiple monoclonal antibodies targeting different antigens or bispecific antibodies to overcome the viral escape phenomenon are of interest.

Dr. Miaomiao Shi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

15 pages, 528 KiB  
Systematic Review
Do Anti-SARS-CoV-2 Monoclonal Antibodies Have an Impact on Pregnancy Outcome? A Systematic Review and Meta-Analysis
by Ennio Conte, Raffaella Di Girolamo, Francesco D’Antonio, Antonio Raffone, Daniele Neola, Gabriele Saccone, Michela Dell’Aquila, Laura Sarno, Marco Miceli, Luigi Carbone and Giuseppe Maria Maruotti
Vaccines 2023, 11(2), 344; https://doi.org/10.3390/vaccines11020344 - 03 Feb 2023
Cited by 2 | Viewed by 1911
Abstract
Monoclonal antibodies (mAbs) have been used as a rescue strategy for pregnant women affected by COVID-19. To explore its impact on maternal-fetal health, we included all observational studies reporting maternal, fetal, delivery and neonatal outcomes in women who underwent mAbs infusion for COVID-19. [...] Read more.
Monoclonal antibodies (mAbs) have been used as a rescue strategy for pregnant women affected by COVID-19. To explore its impact on maternal-fetal health, we included all observational studies reporting maternal, fetal, delivery and neonatal outcomes in women who underwent mAbs infusion for COVID-19. Primary outcome was the percentage of preterm delivery. We used meta-analyses of proportions to combine data for maternal, fetal, delivery and neonatal outcome of women treated with mAbs for COVID-19 and reported pooled proportions and their 95% confidence intervals (CIs) for categorical variables or mean difference (MD) with their 95% confidence intervals for continuous variables. Preterm birth was observed in 22.8% of cases (95% CI 12.9–34.3). Fetal distress was reported in 4.2% (95% CI 1.6–8.2). Gestational hypertension and pre-eclampsia were observed in 3.0% (95% CI 0.8–6.8) and 3.4% (95% CI 0.8–7.5) of cases, respectively. Fetal growth restriction was observed in 3.2% of fetuses (95% CI 0.8–7.0). Secondary prophylaxis with mAbs is currently considered the best treatment option for people with mild to moderate COVID-19 disease. More attention should be paid to infants born from mothers who were treated with mAbs, for the risk of immunosuppression. Full article
(This article belongs to the Special Issue Monoclonal Antibody Research in the Era of COVID-19)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop